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Summary Highly effective treatments for asthma are now available, but many
patients with asthma are still poorly controlled. Guidelines for asthma therapy are
widely disseminated, but they may be considered too complex for general use, and
clinical studies used to support the guidelines are not indicative of ‘real life’. In the
‘real’ world, patients frequently cannot use their inhaler correctly, particularly
pressurised metered-dose inhalers (pMDIs) which require good coordination between
inhaler activation and patient inhalation. Breath-activated inhalers and dry powder
inhalers (DPIs) are much easier to use and result in better lung deposition of the
inhaled drug. Surprisingly, two recent Cochrane meta-analyses recommended that
pMDIs should be preferentially prescribed, as they have similar efficacy to breath-
activated inhalers and DPIs and are cheaper. In reality, DPIs are more cost-effective
as they deposit more drug in the lungs, may improve compliance and result in more
effective asthma control. Improvements in inhaled drug delivery will continue to be
paramount in improving asthma management.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma is a chronic inflammatory airway disorder
that is a serious public health problem in countries
throughout the world. In 1993, the Global INitiative
for Asthma (GINA) was formed and its goals and
objectives were described in the 1995 Workshop
Report Global Strategy for Asthma Management
and Prevention. This report has been widely
distributed and translated into several languages.
In January 2000, the GINA Executive Committee
suggested that the Workshop Report be updated to
incorporate the several advances in the fields of
asthma pathology, genetics, diagnosis, assessment
and treatment detailed in scientific publications
since 1995.1
The aim of the present article was to review
asthma management guidelines and their aims,
discuss how well these aims are being met, detail
any guideline limitations and outline possible
future therapies for asthma.
Asthma management guidelines
Asthma guidelines are now used in virtually
every country and have had important benefits
in improving the management of asthma. The
principles of modern asthma therapy, and overall
goal of every asthma management programme, is
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to achieve control of the disease. According to the
GINA guidelines the goals for successful manage-
ment of asthma are: to achieve and maintain
control of symptoms (including nocturnal symp-
toms); to minimise use of rescue b2-agonists; to
prevent asthma exacerbations; to maintain pul-
monary function as close to normal levels as
possible (peak expiratory flow (PEF) circadian
variationo20%); to maintain normal activity levels
(including exercise); to avoid adverse effects due
to asthma medications; to prevent development of
irreversible airflow limitation; and to prevent
asthma mortality.
The updated guidelines are evidence-based,
ranking evidence in four levels of importance from
randomised controlled studies (evidence A) to
panel consensus (evidence D). The newly formed
Science Committee will also update the guidelines
every year (instead of every 5 years) ensuring
that the guidelines are always up to date, so
providing the best possible advice on asthma
management.
The GINA guidelines recommend a stepwise
approach to pharmacological therapy. The selec-
tion of pharmacological treatment options is made
on the basis of asthma severity, the patient’s
current treatment, pharmacological properties
and availability of anti-asthma medication, as well
as economic considerations. The stepwise approach
to therapy recommends that the number and dose
of asthma medications are increased with increas-
ing asthma severity. The aim is to accomplish the
goals of therapy with the least possible medication.
The premise of the GINA approach to therapy is
that as asthma severity increases, the dose of
inhaled corticosteroids (ICSs) is stepped up and
other classes of drugs are added, particularly long-
acting b2-agonists (LABAs). Once control of asthma
has been achieved and maintained for at least 3
months, a gradual reduction of the maintenance
therapy should be tried in order to identify the
minimum therapy required to maintain control.
Are asthma guidelines improving asthma
control?
Despite the implementation of both national and
international guidelines and the availability of
highly effective medication to combat both asthma
symptoms and the underlying inflammatory compo-
nent of the disease, asthma remains poorly
controlled, indicating that guideline recommenda-
tions are not being adequately implemented. This
state of affairs is global and does not appear to be
due primarily to financial factors; ICSs are rela-
tively inexpensive. The current level of asthma
control in Europe falls far short of the goals for
long-term asthma management (Fig. 1A).2 Rabe
and colleagues2 showed that of 2803 patients with
asthma, 46% reported daytime symptoms, and 30%
reported asthma-related sleep disturbances at
least once a week. Over the course of a year 25%
of patients reported an unscheduled urgent care
visit, 10% reported one or more emergency room
visits and 7% reported overnight hospitalisation due
to asthma.2 Most shocking of all was the fact that
less than one-third of these patients, including
those with severe persistent asthma, were taking
ICSs (Fig. 1B).2 Levels of asthma control were even
worse in the USA for every parameter assessed (Fig.
1A), indicating that this lack of control is not cost-
related, but rather due to poor compliance to
therapy.
The level of asthma control in general practice is
also poor. A high proportion of patients with typical
symptoms of asthma complained of wheezing,
chest tightness, cough and breathlessness, which
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Figure 1 (A) Poor asthma control in both Europe and
USA; and (B) ICS to b2-agonist ratio in patients with mild,
moderate or severe asthma. AIRE: Asthma Insights and
Reality in Europe; AIA: aspirin-induced asthma. Reprinted
with permission from Rabe et al.2
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significantly impacted on their lifestyle and activ-
ities.3 Even patients who felt well had asthma
symptoms, showing that patients underestimate
their own symptoms, and suggests that asthma
control is even worse than anticipated. Frequent
use of short-acting b2-agonists (SABAs) has also
been associated with poor asthma control and an
increased risk of death due to asthma.4 Interest-
ingly, addition of ICSs to SABA therapy reduced the
risk of death due to asthma by 60%. Therefore, if
physicians and patients adhere to asthma manage-
ment guidelines, deaths due to asthma should be
markedly reduced.
Problems associated with guidelines
Inherent flaws with asthma management
guidelines
Not only are physicians and patients not adhering to
asthma management guidelines, but the guidelines
themselves suffer from inherent limitations. Fixed
international guidelines and rigid scientific proto-
cols do not take account of individual differences in
response to treatment and severity of adverse
effects. The guidelines take account of neither the
availability or cost of pharmacological treatments
in different countries, nor give advice on the best
device for delivery of drug to the lungs. Secondly,
for the time-limited general practitioner, the
complexity and length (4170pp.) of the guidelines
are not conducive to rapid understanding and
effective implementation into their treatment
schedules. As 95% of patients with asthma are
treated in general practice, it is vital that doctors
understand the guidelines in order to prescribe the
most effective treatments to their patients. Most
importantly, although the guideline recommenda-
tions are based on the best available scientific
evidence, including randomised controlled studies,
systematic reviews and meta-analyses, each of
these types of study have disadvantages associated
with them.
Perhaps the most powerful evidence used when
reviewing guidelines is systematic reviews and
meta-analyses. These summarise the results of
several studies and therefore, obtain evidence
which would be too weak with individual studies
alone. Of particular importance are the Cochrane
Library Reviews which are now published freely so
that everyone has access to them. However, several
systematic reviews and meta-analyses have serious
flaws. They may bias opinion; in some of them
there has been a powerful influence from pharma-
ceutical companies, where certain studies have
been included but not others. In assessing systema-
tic reviews there are several questions which need
to be addressed. It is important to see if any bias is
apparent in the selection of studies, whether the
criteria used for assessing the validity of included
studies are reported, the methods used to combine
the findings were appropriate and whether the
conclusion(s) are actually supported by the data.
Jadad and colleagues5 carried out a systematic
review of 50 systematic reviews and meta-analyses
of asthma treatment published between 1988 and
1998. They showed that 40 of these had serious
flaws; all of the reviews from the pharmaceutical
industry had serious flaws because they all favoured
the sponsors product.
Randomised controlled clinical studies have
traditionally been considered the pinnacle in
evidence based asthma management excellence,
as they minimise bias and the placebo effect.
However, they do have limitations associated with
them which should be taken into consideration. For
almost all of these studies there are strict exclusion
and inclusion criteria. It is common to find in large
studies that only 10% of the screened patients are
included in the study. Patients are commonly
excluded if they smoke, are elderly or have a
concomitant disease. Patients are also frequently
required to show a predefined bronchodilator
response, have stable asthma, be compliant with
the medication and be able to correctly use
inhalers. All these factors ensure that the study
population, from which we extrapolate to all
patients, is not representative of patients with
asthma in the ‘real world’. Indeed, these limita-
tions of randomised controlled studies may account
for some of the marked discrepancies which have
been observed between clinical studies and patient
reality.
The importance of including a representative
section of the asthmatic population into clinical
studies was examined in a recent study by Chalmers
and colleagues6 (Fig. 2). They showed that cigar-
ette smoking inhibited the inflammatory response
to corticosteroids in patients with asthma. Non-
smoking patients who received high dose flutica-
sone propionate (FP; 1mg/day) showed a signifi-
cant improvement in lung function, correlating to a
concomitant reduction in sputum eosinophilia. But
cigarette smokers had no response to high dose FP
and no reduction in sputum eosinophils, indicating
that cigarette smoking reduces steroid responsive-
ness. Normally, these cigarette smoking patients
are excluded from any clinical study, which may
lead to misleading results, and is one example
where randomised clinical studies can give the
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wrong answer. Viable alternatives to randomised
controlled studies are ‘real world’ or effectiveness
studies and ‘n ¼ 1’ studies. A ‘real world’ study is
more reflective of the population treated in clinical
practice and mimics clinical practice as much as
possible. Large numbers of patients are needed to
account for the many variables which are factored
out of the strictly controlled randomised clinical
study, and there should be no, or minimal,
exclusion or inclusion criteria. Therefore, a ‘real
world’ study has a completely different population
to that included in a randomised controlled clinical
study. Another very valuable approach is the
‘n ¼ 1’ study, where a single patient acts as his/
her own control, treatment being sequentially
changed in order to observe which is the best
treatment for that particular patient.
The discrepancy in results obtained from rando-
mised controlled studies and ‘real-life’ studies was
demonstrated by Robinson and colleagues7 who
examined the effectiveness of add-on montelukast
therapy in a group of 72 patients with asthma
(Fig. 3). The only inclusion criterion was that
participants had to have asthma. The only exclu-
sion criterion was that they should not be on an
anti-leukotriene treatment already. The results
showed that add-on montelukast therapy produced
no improvement in lung function or asthma
symptoms, and no reduction in b2-agonist use. To
allow for any individual difference between pa-
tients, Robinson and colleagues7 also looked at
those patients who had a large response (i.e.X15%
increase in PEF). The results showed that patients
in the placebo group more commonly had a large
response, indicating that montelukast therapy had
no value in that clinical setting. However, the study
was carried out at a specialist hospital and so the
results may not apply to the general population.
Recently, an effectiveness study has been done in
the general population.8 A group of patients with
controlled persistent asthma living in San Diego
(n ¼ 110) were prescribed montelukast (10mg/
day). 44% of them discontinued before completion
of the study because they thought the treatment
was ineffective and 56% continued for a year. At the
end of a year the results showed that montelukast
had a minimal effect, if any. Patients receiving
montelukast showed no difference in the use of
ICSs, systemic steroids or rescue b-agonist. These
results are in marked contrast to results from a
randomised double-blind controlled study in which
montelukast therapy was superior to placebo.9–11
More of these studies are urgently needed to
establish whether anti-asthma treatments are
effective in the ‘real world’.
Non-compliance with asthma treatment
regimen
Asthma may still be poorly controlled because
patients are non-compliant with their therapy.
Reasons for non-compliance are complex and
numerous and may be split into drug and non-drug
factors. Drug factors include difficulty using the
inhaler device, difficult regimens, adverse drug
reactions, cost, reticence to take drugs or difficulty
in acquiring drugs. Non-drug factors are also
barriers to compliance and include such issues as
not understanding the instructions; worrying about
adverse effects; not trusting the doctor; no super-
vision so compliance is never checked; anger about
being ill; and resentment. There may also be
cultural, religious or ethical issues; dislike of being
labelled with the disease; or simply forgetting to
take the treatment.
One factor which is very important for compli-
ance, particularly in severe asthma, is poor
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Figure 2 Effect of cigarette smoking on steroid response
in asthma. Reprinted with permission from Chalmers
et al.6
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Figure 3 Effect of add-on montelukast therapy on
morning and evening PEF in patients with asthma
(n ¼ 72): real world study design. Reprinted with
permission from Robinson et al.7
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perception of the disease. Obviously, if a patient
cannot perceive how severe their symptoms are,
then they are likely to under-estimate the level of
treatment required and not comply with their
management programme. Chetta and colleagues12
investigated patients’ perception of the severity of
their asthma by assessing their perception of
bronchoconstriction after methacholine challenge
(Fig. 4). Results showed that in patients with severe
asthma, the proportion of patients who could not
perceive the severity of their asthma was higher
than those who could perceive it.12 Therefore, it is
important when assessing asthma control that an
objective measure is used, as many patients
(particularly patients with severe asthma) are
unable to perceive how well their symptoms are
controlled.
Lack of focus on device for drug delivery
As mentioned previously, one drawback of the
guidelines is that while they focus on the pharma-
cological treatments available for the management
of asthma, they neglect the delivery devices which
are used to get these treatments into the lung.
This is highly surprising, given that inhaled
therapy in asthma is likely to remain paramount
for the next 10–15 years. When treating asthma,
it is essential that sufficient drug is deposited
to the lungs. The inhaled route of administra-
tion is preferred for many asthma medications,
particularly corticosteroids and b2-agonists, as
drug is targeted directly into the lungs. With
inhaled therapy there is a faster onset of
action time relative to oral administration and
unwanted adverse effects are avoided, by virtue
of the smaller doses and lower systemic
bioavailability. Inhalation devices available for
delivering drugs into the lungs include MDIs,
dry powder inhalers (DPIs) and breath-activated
inhalers.
A systematic review of 24 randomised controlled
studies which compared MDIs, DPIs and breath-
activated inhalers, concluded that there was no
difference between them, recommending that
every patient should use the cheap pressurised
metered dose inhaler (pMDI).13 This is a typical
example of how misleading systematic reviews can
be, as they do not take into account all the issues
that are important. For example, although pres-
surised metered-dose inhalers (pMDIs) may be
cheaper than DPIs, DPIs are easier to use, are
environmentally friendly, do not produce a cold
sensation upon inhalation and deposit more drug
into the lungs. As many as 90% of patients use their
MDI incorrectly,14 as the device requires good
coordination between activation and inspiration,
an optimal inspiratory flow rate15 and effective
training.16 Misuse of pMDIs is frequent and asso-
ciated with poorer asthma control in ICS-treated
patients.17 Common mistakes when using a pMDI
include failure to inhale slowly and continuously
after activation of the inhaler, failure to exhale
fully before inhaling the medication,18,19 activating
the inhaler before inhalation or at the end
of inhalation and concluding inhaler activation
while holding breath.19,20 Even with instruction,
only half of patients can use an MDI correctly
compared with almost 90% of patients using a
breath-activated inhaler or DPI. In addition, as
airway inflammation in the lungs of patients with
asthma extends to the smaller airways,21 it is
important that inhalation devices can deliver anti-
inflammatory drug to all sites of inflammation in
the lungs. Many of the old inhalers, like pMDIs,
deliver most of the drug to the large airways. There
is no doubt that the type of inhaler is just as
important as the class of drug in the long-term
management of asthma.
Mis-classification of asthma severity
Asthma severity is also frequently mis-classified
which means that patients are not adequately
treated. A large study in general practice in the
UK enrolled patients with mild intermittent asthma
based on symptoms and forced expiratory volume
in 1 s (FEV1). However, when these patients were
re-assessed for diagnosis of asthma severity based
on symptoms, FEV1 and medication use, 22% of
them had mild persistent asthma, 15% had moder-
ate persistent asthma and 3% had severe persistent
asthma.22
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Figure 4 Perception of methacholine-induced broncho-
constriction in patients with mild, moderate or severe
asthma. Reprinted with permission from Chetta et al.12
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Future asthma therapy
Current asthma therapy is highly effective which
poses a challenge for the development of new
treatments, since they will need to be safer and
more effective than existing treatments, or offer
some other advantage in long-term asthma man-
agement. What kind of asthma treatments might
we expect in the future? Many specific inhibitors for
systemic treatment are currently being considered.
Since release of mediators from mast cells in
asthma is Immunoglobulin (Ig)-E-dependent, an
attractive approach is to block the activation of
IgE using blocking antibodies that do not result in
mast cell activation. Clinical studies with anti-IgE
(omalizumab) show a steroid sparing effect in
patients with severe asthma,23 indicating that this
treatment might be useful in the control of patients
with allergic asthma who have problems with
adverse effects of oral steroids. However, this
treatment is expected to be expensive. Tumour
necrosis factor (TNF) antibodies (infliximab) or
soluble TNF-receptors (etanercept) are another
logical approach to asthma therapy, since TNF-a
may play a role in amplifying atopic inflammation
through the activation of nuclear factor (NF)-kB
and other transcription factors.
Inhibition of interleukin (IL)-5 is another poten-
tial approach to asthma management, as it is
essential for eosinophilic inflammation. Humanised
monoclonal blocking antibodies to IL-5 have been
developed, and a single injection reduced blood
eosinophils for over 3 months and prevented
eosinophil recruitment into the airways after
allergen challenge.24 However, this treatment had
no effect on the early or late response to allergen
challenge or on airway hyperresponsiveness, sug-
gesting that eosinophils may be less important for
these responses than previously believed. Long-
term clinical studies have also shown lack of
clinical efficacy.25 Infusion of the inhibitory cyto-
kine human recombinant IL-12 has an inhibitory
effect on eosinophils in patients with asthma, but
has significant systemic adverse drug reaction
effects that preclude its clinical development.26
Oral therapies may become more prevalent in
the future for managing asthma. However, oral
therapy is associated with a much greater risk of
systemic adverse effects compared with inhalation
therapy, and therefore needs to be specific for
asthma. Currently, there is a search for small
molecule inhibitors of TNF-a, of which the most
promising are inhibitors of TNF-a converting en-
zyme. Other oral anti-inflammatory treatments
which are currently under development include
inhibitors of phosphodiesterase (PDE) 4, p38 mito-
gen activated protein (MAP) kinase, chemokine
receptors, and transcription factors. PDE4 and p38
MAP kinase inhibitors inhibit TNF-a release from
inflammatory cells. Several small molecule inhibi-
tors of the chemokine receptor CCR3, including
UCB35625, SB-297006 and SB-328437, have been
shown to inhibit eosinophil recruitment in allergen
models of asthma.27,28 Many of the inflammatory
genes that are expressed in asthma are regulated
by NF-kB which has prompted a search for specific
blockers of this transcription factor. However, there
are concerns that inhibition of NF-kB may cause
adverse effects, such as increased susceptibility to
infections, which has been observed in gene
disruption studies when components of NF-kB were
inhibited.
In the absence of ground breaking new discov-
eries in asthma treatment, it is likely that b2-
agonists and ICSs will remain the mainstay of
asthma management strategies for the next 15
years. The use of drug combination inhalers will be
prescribed for patients, who need b2-agonists and
ICS on the daily treatment basis. Further develop-
ments of existing treatments are likely, such as
once daily b2-agonists and ICSs which have a better
safety profile. Inhalation therapy will remain the
optimum method of drug delivery.
Conclusions
Current asthma treatments are highly effective.
Management guidelines have been important in
improving the management of asthma worldwide
but they do have some limitations. For example,
they are based on the best available scientific
evidence, but randomised controlled studies are
highly selective and may not represent patients in
the ‘real world’. Additionally, systematic reviews
and meta-analyses are frequently biased and do not
always provide the right answer. Poor compliance
with treatment is also a major barrier to asthma
management, particularly in the use of ICSs. The
guidelines recommend pharmacological treatments
available for the treatment of asthma but do not
detail the best type of delivery device to deliver
these drugs to the lungs. The choice of inhaler
device is extremely important, as inhalation ther-
apy is likely to persist for many years to come. The
‘ideal’ inhaler should be easy to use and efficient
and therefore, cost-effective as well as being
capable of delivering medication to all sites of
inflammation in the lungs, including the small
airways. Finally, it is highly unlikely that ICSs and
LABAs will be replaced in the next 15 years by any
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new treatment which will be more effective.
Therefore, in the future, inhaler devices are likely
to become more important than development of
new drugs, so the most effective inhalers should be
sought.
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